The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 21, 2011

Filed:

Mar. 15, 2004
Applicants:

Axel Ullrich, Munich, DE;

Werner Risau, Butzbach, DE;

Birgit Millauer, San Francisco, CA (US);

Aviv Gazit, Jerusalem, IL;

Alex Levitzki, Jerusalem, IL;

Inventors:

Axel Ullrich, Munich, DE;

Werner Risau, Butzbach, DE;

Birgit Millauer, San Francisco, CA (US);

Aviv Gazit, Jerusalem, IL;

Alex Levitzki, Jerusalem, IL;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12N 5/10 (2006.01); C07K 14/71 (2006.01);
U.S. Cl.
CPC ...
Abstract

The present invention relates to the use of ligands for the FLK-1 receptor for the modulation of angiogenesis and vasculogenesis. The invention s based, in part, on the demonstration that Flk-1 tyrosine kinase receptor expression is associated with endothelial cells and the identification of vascular endothelial growth factor (VEGF) as the high affinity ligand of Flk-1. These results indicate a major role for Flk-1 in the signaling system during vasculogenesis and angiogenesis. Engineering of host cells that express Flk-1 and the uses of expressed Flk-1 to evaluate and screen for drugs and analogs of VEGF involved in Flk-1 modulation by either agonist or antagonist activities is described. The invention also relates to the use of FLK-1 ligands, including VEGF agonists and antagonists, in the treatment of disorders, including cancer, by modulating vasculogenesis and angiogenesis.


Find Patent Forward Citations

Loading…